On April 15, 2025, Novo Nordisk announced it became aware of several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the U.S. The U.S. Food and Drug Administration issued an alert regarding these products.
The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers, posing serious patient safety risks due to unknown ingredients and manufacturing conditions. This incident directly impacts the integrity and trust associated with the Ozempic brand.
Novo Nordisk emphasized that only FDA-approved versions should be used and is actively working to combat the proliferation of illicit active pharmaceutical ingredients. This issue highlights the ongoing challenge of unlawful compounding and counterfeiting in the GLP-1 market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.